ARTICLES LIST

 

Total Results: 16203

Media ID Source Name Media Type Language Media Name Media Description Keywords Keywords Link to Article
1370 National Cancer Institute Html en Colorectal Cancer Screening (PDQ®)–Health Professional Version Expert-reviewed information summary about tests used to detect or screen for colorectal cancer.
adenomas0.617512
advanced proximal neoplasia0.563212
study0.677803
mortality reduction0.57851
advanced neoplasia0.56302
CRC mortality reduction0.544829
colonoscopy screening0.603021
lesions0.531993
occult blood screening0.64042
CRC mortality difference0.548807
CRC incidence rates0.553335
Engl J Med0.6404
CRC mortality0.70138
CRC cases0.529979
annual FOBT screening0.529584
faecal occult blood0.779217
Ann Intern Med0.763728
complete colonoscopy0.535099
colorectal cancer screening0.676312
colonoscopy0.785471
positive test0.545148
colorectal neoplasia0.540206
colorectal cancer incidence0.537416
detection0.55517
colorectal cancer0.99103
CRC screening0.62285
Abstract0.639242
Screening Colonoscopy Program0.575204
patients0.584805
occult blood testing0.542273
colonoscopy study0.538236
CRC incidence0.62219
systematic review0.578714
lower CRC mortality0.560554
virtual colonoscopy0.591165
CRC screening program0.568518
FIT0.57064
Colorectal cancer mortality0.560865
negative colonoscopy results0.549077
concurrently performed colonoscopy0.531966
fecal occult blood0.884171
CRC0.781593
sigmoidoscopy versus colonoscopy0.551587
colorectal cancer diagnosis0.530522
distal colon0.542283
occult blood test0.71312
sensitivity0.537205
CLICK HERE
1406 National Cancer Institute Html en Endometrial Cancer Screening (PDQ®)–Health Professional Version Expert-reviewed information summary about tests used to detect or screen for endometrial cancer.
underwent endometrial biopsy0.596006
exhibit similar risk0.466243
endometrial thickness cutoff0.594653
endometrial carcinoma0.559295
asymptomatic women0.56298
markedly increased risk0.46896
endometrial biopsy0.602665
TVU0.506165
threshold value0.468657
postmenopausal uterine bleeding0.47677
hormone therapy study0.462599
postmenopausal hormone therapy.0.491288
additional risk factors0.461801
endometrial cavity access.0.584206
high survival rates0.463126
lower survival rates0.458386
endometrial thickness0.608159
endometrial hyperplasia0.560125
white women0.528892
combination estrogen-progesterone therapy0.467831
endometrial cancer0.93723
U.S. women0.465931
abnormal pathologic biopsy0.461543
black women0.483703
women0.713028
unopposed estrogen therapy0.4738
endometrial cancer.0.591335
nonpolyposis colorectal cancer0.479683
endometrial polyps0.561278
endometrial aspiration0.621101
Measuring endometrial thickness0.597601
estrogen therapy0.49246
Cancer Survival Study0.480563
tamoxifen increase patients0.459307
National Cancer Institute0.477348
hormone therapy0.561237
endometrial biopsy specimens0.590423
endometrial cancer incidence0.661899
African American women0.535123
invasive gynecologic cancer0.486102
advanced-stage disease0.478186
breast cancer0.469124
asymptomatic postmenopausal women0.5655
primary endometrial cancer0.608017
Project P-1 trial0.458556
endometrial abnormalities0.576298
National Surgical Adjuvant0.459038
African American women.0.461116
mean age0.461702
CLICK HERE
1450 National Cancer Institute Html en Esophageal Cancer Screening (PDQ®)–Health Professional Version Expert-reviewed information summary about tests used to detect or screen for esophageal cancer.
population-based case-controlled study0.533968
symptomatic gastroesophageal reflux0.581421
columnar-lined esophagus0.552922
curable neoplasms0.466702
Barrett esophagus0.931446
Gastric cardia adenocarcinoma0.596066
lower esophageal sphincter0.581561
standard histological evaluation0.515998
gastroesophageal reflux0.731721
squamous cell cancer0.550703
surveillance method0.472755
risk factors0.526039
annual endoscopy0.479023
esophageal squamous cell0.594095
gastric acid production0.530474
-relaxing drugs0.467279
patients0.488679
Barrett esophagus.0.572924
GERD0.55771
esophageal cancer incidence0.58939
esophageal adenocarcinoma0.818574
esophageal adenocarcinoma.0.53156
human papillomavirus0.478898
new cases0.479464
gastroesophageal reflux disease0.686421
low risk0.472905
esophageal cancer0.594243
H. pylori infections0.535834
infection persisted.0.473995
incidence rate ratio0.524115
reflux esophagitis0.501118
surgical resection0.524265
low-grade dysplasia0.493637
effective surveillance protocol0.524901
surveillance endoscopy0.490968
reflux symptoms0.502651
high-grade dysplasia0.535845
important epidemiological difference0.530091
strong association0.468389
expert gastrointestinal endoscopists0.517855
duodenal ulcers0.473231
risk factor0.481047
Western countries0.470134
successful resection0.474238
cancer mortality.0.469146
gastric infection0.4806
risk0.536679
intramucosal carcinoma0.47033
CLICK HERE
1510 National Cancer Institute Html en Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version Expert-reviewed information summary about the treatment of small cell lung cancer.
Lung Cancer Cooperative0.39126
small-cell lung cancer0.985475
European Lung Cancer0.390681
chemotherapy0.385408
Engl J Med0.425383
American Cancer Society0.349857
Br J Cancer0.382857
limited-stage small-cell lung0.52446
Lung cancer deaths0.390773
tobacco-specific lung carcinogen0.37583
Lung Oncology Group0.359221
Radiat Oncol Biol0.383871
Lung Cancer Group0.384497
oncology group study0.36864
poor-prognosis small-cell lung0.365771
Natl Cancer Inst0.372388
cancer research campaign0.352725
Council Lung Cancer0.415558
stage small-cell lung0.379153
Medical Research Council0.386248
small-cell lung carcinoma0.374311
et al.0.448513
Lung Cancer Working0.375734
extensive-disease small-cell lung0.370168
Research Council Lung0.400238
Cancer Epidemiol Biomarkers0.349186
PUBMED Abstract0.373095
limited-disease small-cell lung0.382414
extensive small-cell lung0.411565
limited-stage small cell0.350265
small cell lung0.655538
prophylactic cranial irradiation0.394396
disease small-cell lung0.396424
extensive-stage small-cell lung0.398504
lung cancer patients0.41432
Cancer Lung Cancer0.412017
Abstract0.488813
Clin Oncol0.605439
cell lung carcinoma0.379947
Oncol Biol Phys0.385351
untreated small-cell lung0.364584
lung cancer risk0.385828
advanced small-cell lung0.364607
Low-dose lung0.356029
cell lung cancer0.62237
better-prognosis small-cell lung0.365507
multiple lung nodules0.359952
thoracic radiotherapy0.411609
limited small-cell lung0.423802
CLICK HERE
1529 National Cancer Institute Html en Male Breast Cancer Treatment (PDQ®)–Patient Version Expert-reviewed information summary about the treatment of male breast cancer.
Clinical breast exam0.284327
Breast Cancer Screening0.314882
breast duct0.265624
cancer spreads0.259464
diagnose breast cancer0.343362
malignant tumor cells0.26356
body0.314871
PDQ cancer information0.299069
Inflammatory Male Breast0.288019
clinical trials0.336788
breast cancer stage0.313107
cancer information summary0.28338
clinical trial0.259026
breast cancer prevention0.329746
breast cancer patients0.302243
lymph node biopsy0.306018
sentinel lymph node0.33726
Inflammatory breast cancer0.359802
NCI PDQ cancer0.260729
early localized breast0.2726
lymph nodes0.375271
breast carcinoma0.267321
metastatic breast cancer0.413709
radiation therapy0.324944
treatment0.354882
abnormal cells0.280815
male breast cancer0.548303
cancer cells0.507692
Cancer Information Service0.257721
specific cancer cells0.266994
breast cancers0.260852
National Cancer Institute0.306996
Breast Cancer Treatment0.32856
hormone therapy0.286562
painful breast lesions0.269444
lymph vessels0.259581
new treatment0.256083
breast cancer cells0.328644
breast cancer0.95341
Hereditary breast cancer0.321208
chest wall0.263619
Recurrent breast cancer0.304665
IIIC breast cancer0.305672
tumor0.317659
treatment options0.26574
cancer information summaries0.256227
comprehensive cancer information0.256173
information0.313083
appropriate cancer treatment0.261896
CLICK HERE
1572 National Cancer Institute Html en Ovarian, Fallopian Tube, and Primary Peritoneal Cancer Screening (PDQ®)–Patient Version Expert-reviewed information summary about tests used to detect or screen for ovarian, fallopian tube, and primary peritoneal cancers.
cancer treatment0.488772
primary peritoneal cancers0.500293
ongoing clinical trials0.488493
following PDQ summaries0.549415
PDQ cancer information0.706697
false-negative test result0.485124
fallopian tube cancer0.565282
primary peritoneal cancer0.815712
clinical trials0.639646
test result0.547906
Peritoneal Cancer Prevention0.54551
cancer information summary0.620799
PDQ Ovarian0.537752
clinical trial0.497999
breast cancer prevention0.513915
ovarian cancer0.852752
false-positive test result0.536437
cancer patients0.484043
latest published information0.494395
peritoneal cancer form0.545913
NCI’s PDQ0.505993
cancer symptoms0.504824
NCI PDQ cancer0.581936
tests0.532273
certain types0.48682
black women0.481021
PDQ Screening0.526415
peritoneal cancer screening0.608486
cancer prevention0.549601
screening tests0.485985
Cancer Information Service0.531657
fallopian tube0.68704
Prevention Editorial Board0.543082
treatment clinical trials0.485965
National Cancer Institute0.650104
PDQ documents0.496817
cancer doctors0.479641
new treatment0.493333
Cancer screening trials0.564141
Ovarian epithelial cancer0.582644
Cancer Care page0.517342
PDQ database0.501449
PDQ summary0.536253
fallopian tubes0.578652
cancer information summaries0.539976
health professional versions0.477788
comprehensive cancer information0.539707
cancer0.983489
CLICK HERE
1806 National Cancer Institute Html es Tratamiento del cáncer de estómago (PDQ®)–Versión para profesionales de salud Resumen de información revisada por expertos acerca del tratamiento del cáncer de estómago.
after d2 gastrectomy0.313513
gastrectomía d20.31496
Cunningham D0.34388
Macdonald JS0.318723
Chemoradiotherapy after surgery0.344328
randomised controlled0.319618
combined modality therapy0.360634
mejoría significativa0.31176
Stenning SP0.310838
intergroup trial calgb0.31542
Postoperative adjuvant chemoradiation0.322032
after ci 5-fu0.317294
fase iii0.364462
Estados Unidos0.347269
with s-10.314235
randomized trial comparing0.314288
quimiorradioterapia posoperatoria0.360835
ensayo rtog-99040.324678
patients with0.484752
adyuvante versus tasa0.360686
supportive care0.325372
Clinical Oncology0.311085
Perioperative chemotherapy versus0.334581
chemotherapy plus best0.312401
Smalley SR0.318682
with surgery0.339493
Ajani JA0.354002
or gastroesophageal junction0.340588
ensayo swog-s04250.324881
Allum WH0.311046
quimiorradioterapia adyuvante versus0.364135
estadio ib0.338006
gastrectomía curativa d20.319296
Van Cutsem E0.313883
Benedetti J0.318647
quimioterapia perioperatoria0.352185
gastric carcinoma0.325701
gastric cancer0.935626
Clin Oncol0.612714
or gastro-oesophageal junction0.317111
trial comparing0.314461
supportive care with0.324232
Winter K0.319459
Gastric Cancer Study0.317632
chemotherapy versus surgery0.338116
grupo s-10.317965
Okawara GS0.319919
care with best0.314996
quimioterapia posoperatoria0.31518
CLICK HERE
1943 National Cancer Institute Html es Síndromes cardiopulmonares (PDQ®)–Versión para profesionales de salud Resumen de información revisada por expertos acerca de las afecciones comunes que producen síntomas en el tórax. Los síndromes cardiopulmonares que se exponen en este sumario son la disnea relacionada con el cáncer, el derrame pleural maligno, el derrame pericárdico y el síndrome de la vena cava superior.
pleural catheter0.17861
Ripamonti C0.130559
dificultad respiratoria0.26023
malignant effusion0.115362
lung cancer0.190962
Sin embargo0.114284
end-of-life patients with0.119385
indwelling pleural catheter0.162022
Dudgeon DJ0.13043
fármacos pleurales esclerosantes0.112004
disfunción muscular respiratoria0.121219
Hematol Oncol Clin0.143013
hypoxemic patients with0.118489
patients receiving chemotherapy0.111162
Cancer Organisation Thoracic0.117844
antitusivos opioides0.112496
recurrent symptomatic malignant0.110714
patients with0.625852
insuficiencia cardiaca0.134239
Pain Symptom Manage0.478956
randomized controlled0.112081
pleural fluid0.136904
Cancer Dyspnea Scale0.146703
Moroni M0.110841
Care Cancer0.128094
pleural catheter vs0.135869
Physiol Neurobiol0.116436
as symptomatic treatment0.110943
derrame maligno fracasa0.114534
obstructiva crónica0.135859
vías respiratorias0.205286
tunnelled pleural catheter0.139919
tos crónica causa0.111919
prospective randomized0.110614
pleural effusions with0.149859
Intern Med0.132242
Clin Oncol0.11762
Med Pediatr Oncol0.111608
Clin North Am0.136363
Bruera E0.203018
systematic review0.116364
Oncol Clin North0.140711
American Thoracic Society0.114142
as palliative treatment0.110799
malignant pleural effusions0.900896
Crit Care Med0.171232
symptomatic malignant0.122652
alone versus0.11566
compared with0.110951
CLICK HERE
2082 National Cancer Institute Html en Cancer Clusters A fact sheet that describes what constitutes a cancer cluster and the process for reporting and investigating suspected clusters.
major risk factor0.385962
specific environmental hazards0.38074
rare cancer0.409989
website uses data0.380594
cancer trends0.398646
individual cancer clusters0.469731
number0.405815
investigators0.393508
Health Hazard Evaluation0.380995
Disease Control0.519415
Health Consultations page0.381331
cancer cluster0.895701
cancer clusters0.841764
National Center0.381056
ATSDR regional offices0.380684
different geographic area0.38274
cluster investigations0.411002
true cancer clusters0.482566
public health assessments0.472612
statistically significant difference0.384068
vinyl chloride0.380035
specific cancer type0.434002
primary cancer0.413707
U.S. Census Bureau0.37492
specific hazardous substances0.37613
different cancer types0.429181
state health department0.450442
total number0.385248
cancer cases0.749447
health departments0.457783
NCI analyze variations0.380726
local health departments0.450682
geographic area0.518161
specific geographic area0.389344
health surveillance programs0.382617
people0.378106
epidemiologic study0.378396
agency gathers information0.381997
statistically significant excess0.455543
secondary cancer0.393665
cancer0.954313
state cancer registries0.443891
cancer cluster—that0.391887
Disease Registry0.381886
specific time period0.392616
Toxic Substances0.380998
cancer death rates0.436653
cancer incidence0.401099
Cancer Mortality Maps0.435229
CLICK HERE
3448 National Cancer Institute Html es Prevención del cáncer de ano (PDQ®)–Versión para profesionales de salud Sumario de información revisada por expertos sobre factores que pueden influir en el riesgo de presentar cáncer de ano, y sobre las investigaciones dirigidas a la prevención de esta enfermedad.
Malignancies Among Cancer0.376997
long-term risk0.317273
lesiones precursoras0.331467
Goldstone S0.318721
American Cancer Society0.336812
NIH Pub0.338006
Giuliano AR0.319633
CA Cancer0.335938
Engels EA0.334211
nationwide cohort study0.318123
Second cancers among0.32229
new malignancies0.372644
Frisch M0.318875
anal hpv0.38502
Ron E0.319704
risk factors0.340585
anal intraepithelial neoplasia0.348272
Natl Cancer Inst0.37761
papillomavirus-related gynecologic neoplasm0.319719
cancers among0.324258
human papillomavirus0.471776
Anal carcinoma0.320142
Cancer Epidemiology0.319322
hpv infection0.344517
SEER Cancer Statistics0.322144
have sex with0.39684
cohort study0.328375
who have sex0.393593
anal intra-epithelial neoplasia0.321943
Fraumeni JF Jr0.315722
Madeleine MM0.330833
SEER Cancer0.386157
SEER Cancer Registries0.37953
Infect Dis0.350074
Cancer Facts0.318636
Curtis RE0.320735
New Malignancies Among0.340351
National Cancer Institute0.584605
among men0.315549
características histológicas0.334238
Among Cancer Survivors0.378869
papillomavirus-associated anal cancers0.323075
Palefsky JM0.334575
Freedman DM0.321699
Cancer Survival Among0.320203
anal cancer0.954929
New malignancies following0.338599
sexual practices0.336294
cuello uterino0.534342
CLICK HERE

 

 

 

Terms of Use | Privacy Policy
©2017 ARCHES Technology. All Rights Reserved.